Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Maze Therapeutics, Inc.NASDAQ: MAZE
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $33.7M rose 22.2% year over year, behind the +28.4% change in trailing-twelve-month research & development. Sequentially, it rose 22.2% from the prior quarter. Over 3 fiscal years it compounded at +7.1% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +22.2% toward the trailing-twelve-month pace of +28.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 108.45M USD
- Year-over-year change
- +29.9%
- 3-year CAGR
- +7.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 108.45M | +29.9% |
| FY2024 | 2024-12-31 | 83.5M | +12.9% |
| FY2023 | 2023-12-31 | 73.95M | -16.2% |
| FY2022 | 2022-12-31 | 88.19M | — |
Research & Development vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +28.4% is the 4th highest of 8, against a peer median of +28.1%.
- Research & development amounts to 572.9% of revenue for MAZE, versus a peer median of 90.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $433.31M USD | -14.7% | -11.3% | 43.0% | |
| LTM Sep 2026 | $245.55M USD | +16.8% | -3.2% | 37.7% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $132.66M USD | +56.0% | — | 137.8% |
| LTM Mar 2026 | $114.57M USD | +28.4% | +7.1% | 572.9% | |
| FY2025 | €83.61M EUR | -8.0% | +11.4% | 1865.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $83.27M USD | +36.9% | +34.3% | 807.2% |
| LTM Mar 2026 | $74.32M USD | +33.9% | +24.8% | 17.4% | |
| LTM Mar 2026 | $26.95M USD | +28.1% | +46.4% | — | |
| Peer median (excluding MAZE) | — | +28.1% | +18.1% | 90.4% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 2.4M |
| Gross Profit | 0 | 0 | 167.5M | (2.4M) |
| Gross Margin | — | — | 100.0% | — |
| Research & Development | 88.19M | 73.95M | 83.5M | 108.45M |
| Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M |
| Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M |
| EBITDA | (111.12M) | (96.33M) | 56.7M | (128.72M) |
| EBITDA Margin | — | — | 33.9% | — |
| Operating Income | (111.03M) | (98.55M) | 57.59M | (142.9M) |
| Operating Margin | — | — | 34.4% | — |
| Interest Income | 2.03M | 1.97M | 4.65M | 11.78M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.91M) | (1.86M) | (4.18M) | 11.78M |
| Income Before Tax | (114.94M) | (100.42M) | 53.4M | (131.12M) |
| Pre-Tax Margin | — | — | 31.9% | — |
| Income Tax Expense | 0 | 0 | 1.17M | 0 |
| Net Income | (114.94M) | (100.42M) | 52.23M | (131.12M) |
| Net Margin | — | — | 31.2% | — |
| EPS (Basic) | (2.63) | (2.29) | 0.08 | (3.05) |
| EPS (Diluted) | (2.63) | (2.29) | 0.08 | (3.05) |
| Weighted Avg Shares | 43.78M | 43.78M | 43.8M | 42.98M |
| Weighted Avg Shares (Diluted) | 43.78M | 43.78M | 43.8M | 42.98M |
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.